January 16, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Sheena K. Aurora, MD, as Vice President of Medical Affairs – Migraine...

November 20, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that a narrative review of dihydroergotamine (DHE) was published online in Headache, the official journal...

Poster presented at the International Headache Congress (IHC) 2019 in Dublin, Ireland. Authors: Kelsey H. Satterly, Stephen B. Shrewsbury, John Hoekman Objective: To compare plasma exposure in the first two hours following administration of INP104 (dihydroergotamine mesylate [DHE] by Precision Olfactory Delivery [POD®]), Migranal® Nasal Spray, D.H.E. 45® (IV) or MAP0004 (oral inhalation)...

Poster presented at the International Headache Congress (IHC) 2019 in Dublin, Ireland. Authors: Sutapa Ray, Stephen Shrewsbury Objective: Ergot use in obstetrics dates back to 1100 BC in China, 370 BC by Hippocrates and 1808 in the US. However, it was not until 1918 that ergotamine was isolated, subsequently modified to DHE and...

Poster presented at International Headache Congress (IHC) 2019 in Dublin, Ireland Authors: Stephen B. Shrewsbury, Maria Jeleva, Jasna Hocevar-Trnka, Meghan Swardstrom Objective: 1) Establish safety and tolerability of repeated INP104 exposure 2) Explore efficacy of INP104 in migraineurs (compared to baseline) 3) Explore INP104 effects on Quality of Life and Healthcare Utilisation...

Impel is a proud sponsor of the 2nd annual Mississippi Headache Symposium, bringing together providers and patients for a great educational event. You can meet us at our booth for more information on our migraine program. ...

September 5, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it will present four scientific abstracts at the 19th Congress of the International Headache...